Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Surgery Today"
DOI: 10.1007/s00595-017-1527-5
Abstract: PurposeThis retrospective study investigates the safety of neoadjuvant chemotherapy with oxaliplatin capecitabine (CapeOx), followed by laparoscopic surgery, for lower rectal cancer, and its efficacy in preserving the sphincter.MethodsTen patients with diagnosed lower rectal cancer received… read more here.
Keywords: capeox; surgery; rectal cancer; lower rectal ... See more keywords
Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2018.11.001
Abstract: Micro‐Abstract Proton pump inhibitors (PPIs) have been implicated in the impaired absorption of various oral oncologic therapies. Significantly reduced 3‐year recurrence‐free survival rates were seen in our retrospective chart review of stage II‐III colorectal cancer… read more here.
Keywords: recurrence; capeox; colorectal cancer; ppi recipients ... See more keywords
A retrospective analysis of the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) and docetaxel plus S-1 (DS) as adjuvant chemotherapy for pathological stage III (p stage III) gastric cancer (GC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.342
Abstract: 342 Background: Adjuvant chemotherapy following surgical resection is the standard treatment for patients with p stage III GC in Japan. Although CapeOX and DS are available for adjuvant chemotherapy for stage III GC, there is… read more here.
Keywords: stage iii; analysis; stage; adjuvant chemotherapy ... See more keywords
A multicenter randomized phase II study of trastuzumab biosimilar (CT-P6) and chemotherapy (SOX or CapeOX) in HER2-positive advanced/recurrent gastric cancer (KSCC: TROX study).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4029
Abstract: 4029 Background: The efficacy and safety of the trastuzumab biosimilar (CT-P6) combined with S-1/oxaliplatin (SOX) or capecitabine/oxaliplatin (CapeOX) were investigated in patients with HER2-positive advanced or recurrent gastric cancer who had not previously received chemotherapy.… read more here.
Keywords: cancer; recurrent gastric; gastric cancer; trastuzumab biosimilar ... See more keywords